Improved in vivo stability and tumor targeting of bismuth-labeled antibody.

We have used a series of bifunctional chelating agents to prepare 206Bi-labeled monoclonal antibody and have assessed the in vivo stability and tumor targeting of these conjugates in the Rauscher murine erythroleukemia model. Several derivatives of diethylenetriaminepentaacetic acid [the dicyclic dianhydride of diethylenetriaminepentaacetic acid (ca-DTPA), 2-(p-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid (SCNBzDTPA), and 2-(p-isothiocyanatobenzyl)-5(6)-methyl-diethylenetriaminepentaacet ic acid (MxDTPA)], as well as a macrocyclic polyazacycloalkane-N-acetic acid [2-(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-N ,N',N",N"'- tetraacetic acid (DOTA)], were conjugated to monoclonal antibody 103A, which is specific for gp70 expressed on Rauscher virus-infected cells. The stability in vivo of 206Bi chelate-103A conjugates was first evaluated in normal mice by determining the levels of 206Bi in blood and kidney, since these were the organs in which free 206Bi, 206Bi-caDTPA-103A, and 35S-103A accumulated. The biodistribution of 206Bi administered as a chelate of caDTPA-103A was virtually indistinguishable from that of free 206Bi, indicating a low degree of in vivo stability of this bismuth chelate when compared to biosynthetically labeled 35S-103A. There was a progressive increase in the 206Bi levels observed in blood when the series of 103A conjugates prepared using SCNBzDTPA, MxDTPA, and DOTA was compared to 206Bi administered free or as a caDTPA-103A chelate. At 1 h after injection into normal mice, the blood level of 206Bi-DOTA-103A was 25-fold greater than that observed for 206Bi-caDTPA-103A and the level in kidney was 6-fold less, values that did not differ significantly from those observed for 35S-103A. Targeting to leukemic spleen was increased by 10-fold when the DOTA conjugate was used; the tumor level was 90% injected dose/g for DOTA, as compared to only 9% injected dose/g for caDTPA-103A at 1 h after injection. Use of the DOTA chelator also reduced by 7-fold the level of uptake by the kidney in the leukemic animals. We, therefore, conclude that the chelator DOTA is a promising reagent for the delivery of 212Bi-antibody conjugates to vascularized tumors under conditions that require targeting via the circulatory system.

[1]  T. Waldmann,et al.  Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. , 1989, Cancer research.

[2]  H. Sakahara,et al.  Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: comparison of biodistribution of 75Se-, 111In-, and 125I-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice. , 1989, Cancer research.

[3]  A. Herbst,et al.  The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma. , 1989, American journal of obstetrics and gynecology.

[4]  R. Weichselbaum,et al.  The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy. , 1989, Gynecologic oncology.

[5]  J. P. Cox,et al.  Synthesis of a kinetically stable yttrium-90 labelled macrocycle–antibody conjugate , 1989 .

[6]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .

[7]  P W Doherty,et al.  Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  S. Denardo,et al.  The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex. , 1988, Journal of the American Chemical Society.

[9]  C. Coleman,et al.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates. , 1988, Science.

[10]  H. Sakahara,et al.  Relationship between in vitro binding activity and in vivo tumor accumulation of radiolabeled monoclonal antibodies. , 1988, Journal of Nuclear Medicine.

[11]  A. M. Friedman,et al.  An improved generator for the production of 212Pb and 212Bi from 224Ra. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[12]  R. Squire,et al.  Specific radioimmunotherapy using 90Y-labeled monoclonal antibody in erythroleukemic mice. , 1987, Cancer research.

[13]  D. E. Simpson,et al.  Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies , 1986 .

[14]  P. Joseph,et al.  Nuclear magnetic resonance and gamma camera tumor imaging using gadolinium-labeled monoclonal antibodies. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  T. Waldmann,et al.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. L. Childs,et al.  Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  M. Strand,et al.  Stability, targeting, and biodistribution of scandium-46- and gallium-67-labeled monoclonal antibody in erythroleukemic mice. , 1985, Cancer research.

[18]  S. Larson,et al.  Monoclonal antibodies in nuclear medicine. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  J. Murray,et al.  Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5. , 1985, Cancer research.

[20]  R. Begent.  Recent advances in tumour imaging. Use of radiolabelled antitumour antibodies. , 1985, Biochimica et biophysica acta.

[21]  T. Wensel,et al.  Metal chelates as probes of biological systems , 1984 .

[22]  R. W. Baldwin,et al.  Monoclonal antitumour antibodies for tumour detection and therapy. , 1984, Behring Institute Mitteilungen.

[23]  D. Scheinberg,et al.  Generator-Produced Bi-212: Chelated to Chemically Modified Monoclonal Antibody for Use in Radiotherapy , 1984 .

[24]  S. Larson,et al.  Radioimmunodetection and radioimmunotherapy. , 1984, Cancer investigation.

[25]  D. Scheinberg,et al.  Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. , 1983, Cancer research.

[26]  D. Scheinberg,et al.  Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. , 1982, Science.

[27]  D. Scheinberg,et al.  Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. , 1982, Cancer research.

[28]  A. Wolf,et al.  Astatine-211--tellurium radiocolloid cures experimental malignant ascites. , 1981, Science.

[29]  Gunnar F. Nordberg,et al.  Handbook on the Toxicology of Metals , 1979 .

[30]  G. Krejcarek,et al.  Covalent attachment of chelating groups to macromolecules. , 1977, Biochemical and biophysical research communications.

[31]  J. Szymańska,et al.  Binding of bismuth in the kidneys of the rat: the role of metallothionein-like proteins. , 1977, Biochemical pharmacology.

[32]  A. Nunn,et al.  Covalent attachment of metal chelates to proteins:the stability in vivo and in vitro of the conjugate of albumin with a chelate of 111indium. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.